Skip to main content

Table 1 Patient characteristics

From: Taking antithrombic therapy during emergency laparoscopic cholecystectomy for acute cholecystitis does not affect the postoperative outcomes: a propensity score matched study

 

Before match

After match

ATT (n = 30)

Non-ATT (n = 120)

P value

ATT (n = 22)

Non-ATT (n = 22)

P value

Age

77 (44–90)

70 (25–100)

0.065

77 (59–90)

72 (51–92)

0.549

Sex (Male/Female)

23/7

70/50

0.092

15/7

15/7

1.000

BMI (kg/m2)

23.1 (3.9)

23.9 (3.8)

0.302

22.5 (3.4)

22.4 (3.1)

0.973

ASA-PS (1,2/3,4)

16/14

105/15

< 0.001

14/8

17/5

0.510

CCI

1 (0–6)

0 (0–4)

0.001

1 (0–6)

1 (0–4)

0.714

TG18 grade (1/2,3)

8/22

78/42

< 0.001

8/14

10/12

0.760

WBC (104/µL)

1.5 (0.5)

1.3 (0.5)

0.039

1.3 (0.5)

1.5 (0.4)

0.489

Hb (g/dL)

12.7 (1.7)

13.6 (2.0)

0.028

12.7 (1.4)

12.7 (2.4)

0.970

Plt (104/µL)

21.0 (7.5)

23.2 (8.1)

0.180

21.5 (8.1)

23.1 (7.1)

0.489

CRP (mg/dL)

14.8 (0.1–44.1)

4.0 (0.0–18.4)

0.004

15.8 (0.1–44.1)

2.4 (0.0–30.9)

0.022

Alb (g/dL)

3.4 (0.7)

3.7 (0.7)

0.007

3.4 (0.7)

3.7 (0.8)

0.190

Total bilirubin (mg/dL)

1.2 (0.2–5.4)

1.0 (0.2–16.8)

0.195

1.1 (0.2–5.4)

0.9 (0.4–10.3)

0.597

AST

25 (14–513)

24 (11–1243)

0.842

24 (14–201)

23 (11–390)

0.787

ALT

19 (6–515)

24 (6–866)

0.491

17 (6–114)

20 (6–866)

0.526

ALP

273 (155–1369)

258 (115–1477)

0.521

256 (155–627)

270 (121–1477)

0.771

γGTP (IU/L)

50 (9–450)

40 (12–572)

0.932

47 (9–128)

43 (14–572)

0.488

Cr

0.8 (0.4–7.3)

0.8 (0.3–7.1)

0.116

0.8 (0.5–7.3)

0.8 (0.5–7.1)

0.953

PT-INR

1.2 (1.0–2.0)

1.1 (0.9–1.4)

< 0.001

1.2 (1.0–1.6)

1.0 (0.9–1.3)

0.001

APTT (s)

41.1 (26.6–76.1)

33.5 (21.4–53.6)

< 0.001

   

ACT (%)

7 (23.3)

  

4 (18.2)

  

APT (%)

25 (83.3)

  

18 (81.8)

  

Multiple dosage (%)a

5 (16.7)

  

2 (9/1)

  

Duration until operation from onset

3 (1–10)

2 (1–30)

0.088

3 (1–10)

3 (1–10)

0.157

  1. Mean (SD) or median (range)
  2. ACT, anticoagulation therapy; APTT, activated partial thromboplastin time; ATT, antithrombic therapy; BMI, body mass index; ASA-PS, American Society of Anesthesiologists-Physical Status; CCI, Charlson Comorbidity Index: TG18, Tokyo guideline 2018; WBC, white blood cell; Hb, hemoglobin, Plt, platelet; CRP, c-reactive protein; Alb, albumin, γGTP, gamma glutamyl transpeptidase; PT-INR, prothrombin time-international normalized ratio
  3. aMultiple dosage of APT or combination of ACT and APT